FOXP3 and Autoimmunity: To further evaluate risks of autoimmunity and inflammation, we evaluated the rate of divisions of conventional CD4+ T cells and RAG1-/- cells in vivo, and found no increase in ASO FOXP3 treated group (Supplementary Figure 13D).